Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial
Open Access
- 29 October 2025
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-10
Abstract
Background: The COVID-19 pandemic gave rise to clinical trials focused on systematic, accurate primary data capture, and reduced reliance on source data verification (SDV). Here, we report on a natural experiment that allowed us to assess the quality, cost, and impact of this approach compared to traditional SDV. Methods: The I-SPY COVID trial (NCT04488081) was a multicenter, open-label, platform trial that employed a streamlined daily checklist, daily capture of labs and medications, and centralized monitoring to ensure accurate data collection in lieu of SDV. The trial enrolled 1,111 patients in 11 drug arms with severe COVID-19. After the trial arms were closed, extensive retrospective SDV was performed on 333 (30.0%) patients, including 10,101 of 44,486 (23%) electronic case report forms (eCRFs), allowing us to evaluate the impact of our strategy on data integrity, outcomes, and costs. Results: We find that retrospective SDV results in changes to 0.36% (1,234 / 340,532) of data fields. It results in no changes to the type of outcome recorded (death, recovery, or censored), but changes in the day of recovery in 9 instances, by a median of 2 days (range 1-7). Two additional AEs are added during SDV that had not previously been captured. Costs associated with retrospective SDV of 23% eCRFs are 61,073 person-hours at a cost of $6.1 M. Conclusions: Extensive SDV does not change any results or conclusions of the I-SPY COVID trial, which was designed with a systematic strategy for data capture, monitoring, and safety. This strategy could improve the efficiency of clinical trials and eliminate the need for manual SDV.Keywords
Funding Information
- U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority
This publication has 30 references indexed in Scilit:
- The Integration of Clinical Trials With the Practice of MedicineJAMA, 2024
- Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trialeClinicalMedicine, 2023
- Evaluating the evaluators - Developing evidence of quality oversight effectiveness for clinical trial monitoring: Source data verification, source data review, statistical monitoring, key risk indicators, and direct measure of high risk errorsContemporary Clinical Trials, 2022
- Risk-Based Monitoring in Clinical Trials: Increased Adoption Throughout 2020Therapeutic Innovation & Regulatory Science, 2022
- Harmonizing Protocol Complexity with Resource Management and Capacity Planning at Clinical Research SitesTherapeutic Innovation & Regulatory Science, 2020
- Clinical trial costs go under the microscopeNature Medicine, 2019
- A comparative effectiveness study of eSource used for data capture for a clinical research registryInternational Journal of Medical Informatics, 2017
- Trends in clinical trial design complexityNature Reviews Drug Discovery, 2017
- Impediments to Clinical Research in the United StatesClinical Pharmacology & Therapeutics, 2012
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993